Compare Ascendis Pharma A/S (ASND) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Domino's Pizza, Inc. — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Domino's Pizza, Inc. trades at $353.5 (market cap $11.82B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.23% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DPZ | |
|---|---|---|
Market Cap | $16.67B | $11.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $467.30 |
52-Week Low | $189.74 | $282.89 |
Enterprise Value | $17.04B | $16.78B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
DPZ trades at $353.72, up 1.69% today, with a bullish technical signal from moving averages and support at $352. Revenue grew to $4.94B in 2025, with net income of $601.70M, though recent quarters saw EPS misses. The company launched a new individual pizza product in August 2026 to boost sales, as reported by WSJ on August 11, 2026.
Outlook is mixed: analyst consensus is a Buy with a $371.67 target, but high debt and weak Q3 2026 EPS expectations pose risks. Growth depends on new product success and cost management amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
